Sponsored Links
| Boston Scientific Completes Enrollment In Clinical Trial Evaluating Next-Generation Nitinol Stent To Treat Iliac Artery Disease |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
Boston Scientific Corporation (NYSE: BSX) announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow to the muscles (claudication)... Read more: Clinical Trials / Drug Trials News From Medical News Today
|